Seres Therapeutics (MCRB) PT Lowered to $32 at Piper Sandler, Following Clinical Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Price: $1.83 -6.63%
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $32.00 (from $40.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seres Therapeutics (MCRB) Tops Q3 EPS by 1c
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
